{"title":"PharmaNews","authors":"Kompass Dermatol","doi":"10.1159/000494075","DOIUrl":"https://doi.org/10.1159/000494075","url":null,"abstract":"Die Europäische Kommission (European Commission, EC) hat Nivolumab (Opdivo®) zur adjuvanten Behandlung des Melanoms mit Lymphknotenbeteiligung oder Metastasierung nach vollständiger Resektion bei Erwachsenen zugelassen. Diese Indikation gilt sowohl für Melanompatienten mit BRAFMutation als auch für Patienten mit Wildtyp-BRAF. Damit ist Nivolumab der erste und einzige Programmed Death-1 (PD-1)-Inhibitor, der in der Europäischen Union (EU) eine Zulassung im adjuvanten Setting erhalten hat. Der Wirkstoff ist in der EU nun für 8 Indikationen bei 6 verschiedenen Tumorarten indiziert [1].","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122087314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PharmaNews","authors":"","doi":"10.1159/000494074","DOIUrl":"https://doi.org/10.1159/000494074","url":null,"abstract":"In die multizentrische, 1-armige, offene Phase-II-Studie wurden 88 Patienten mit einem histologisch bestätigten metastasierten Merkelzellkarzinom eingeschlossen, deren Erkrankung unter oder nach Chemotherapie zur Behandlung eines Erkrankungsstadiums mit Fernmetastasen fortgeschritten war. Die Patienten wiesen eine Lebenserwartung von über 3 Monaten auf und standen über einen Zeitraum von mindestens 18 Monaten unter Nachbeobachtung [1, 2].","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125170862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chronische Prurigo: eine ungewöhnliche Manifestation des Hodgkin-Lymphoms","authors":"Shireen Dumont, Marc Péchère, L. Toutous Trellu","doi":"10.1159/000492483","DOIUrl":"https://doi.org/10.1159/000492483","url":null,"abstract":"Hintergrund: Prurigo nodularis ist eine Krankheit unbekannten Ursprungs, die durch papulonoduläre Effloreszenzen und starken Juckreiz charakterisiert ist. Hodgkin-Lymphome manifestieren sich anfänglich oft mit unspezifischen Symptomen. Eine Assoziation zwischen systemischen malignen Erkrankungen und kutanen Manifestationen ist schon seit Langem dokumentiert. Wir berichten hier über einen Fall von Prurigo nodularis als Erstmanifestation eines Hodgkin-Lymphoms. Fall: Eine 35-jährige Frau stellte sich mit seit 2 Jahren bestehendem Pruritus vor. Nachdem zunächst Wanzen als Ursache diagnostiziert wurden, der Pruritus jedoch auch nach Bekämpfung der Insekten anhielt, kamen papulonoduläre Läsionen hinzu, die dem Bild einer chronischen Prurigo entsprachen. Juckreiz und Schmerzen sprachen auf keine Behandlung an. Die Patientin hatte keine einschlägige Vorgeschichte bzw. lagen auch keine früheren klinischen und radiologischen Untersuchungsergebnisse oder Laborbefunde vor. Eine Lymphadenopathie wurde 2 Jahre nach dem Auftreten der ersten Symptome entdeckt. Eine Lymphknotenbiopsie ergab ein nodulär-sklerosierendes Hodgkin-Lymphom. Eine Chemotherapie wurde eingeleitet, und die Hautläsionen gingen zurück. Schlussfolgerung: Der hier beschriebene Fall einer chronischen Prurigo als erstem Anzeichen einer systemischen malignen Erkrankung unterstreicht, wie wichtig es ist, bei diesen Patienten sowohl anfangs als auch im gesamten Verlauf bei der Diagnose systematisch vorzugehen, insbesondere wenn durch die Behandlung keine Besserung der Beschwerden eintritt. Unser Fall könnte die Rolle der Bildgebung im Management und Follow-up der persistierenden Prurigo nodularis in Frage stellen. Übersetzung aus Case Rep Dermatol 2018;10:122-126 (DOI: 10.1159/000489161)","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131416803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Management von paraneoplastischem Pruritus","authors":"Brandon Rowe, Gil Yosipovitch","doi":"10.1159/000492551","DOIUrl":"https://doi.org/10.1159/000492551","url":null,"abstract":"Paraneoplastischer Pruritus tritt als systemische Reaktion auf eine zugrunde liegende maligne Erkrankung auf. Paraneoplastischer Pruritus ist am häufigsten mit malignen lymphoproliferativen Erkrankungen sowie soliden Tumoren, die zu Cholestase führen, assoziiert. Paraneoplastischer Pruritus kann sich sowohl ohne primären Hautausschlag manifestieren als auch in Verbindung mit dermatologischen Erkrankungen wie Erythrodermie, Acanthosis nigricans, Dermatomyositis (DM), transitorischer akantholytischer Dermatose (Morbus Grover) oder eruptiver seborrhoischer Keratose. Die Behandlung des paraneoplastischen Pruritus beruht primär auf der Behandlung der zugrunde liegenden malignen Erkrankung, die ursächlich für die systemische Reaktion ist. Wenn die maligne Erkrankung nicht auf Behandlung anspricht, können andere Therapien beim paraneoplastischen Pruritus wirksam sein, wie selektive Serotonin-Wiederaufnahmehemmer, Mirtazapin, Gabapentin, Thalidomid, Opioide, Aprepitant und Histon-Deacetylase-Inhibitoren. Übersetzung aus Curr Probl Dermatol. Basel, Karger, 2016, vol 50, pp 149-154 (DOI: 10.1159/000446060)","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"163 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132793857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Informationsinfarkt","authors":"H. Walach","doi":"10.1159/000493115","DOIUrl":"https://doi.org/10.1159/000493115","url":null,"abstract":"und die Weggedrückten wissen, dass wir nicht mit ihnen kommunizieren wollen. Erklärungsnot, Peinlichkeiten, Schwindeleien. Die ganze Maschinerie ist ja Teil eines gigantischen Informationsinfarktes, auf den wir zusteuern, wenn wir nicht schon mittendrin sind. Denn das Handy ist ja gleichzeitig Peilstation, sodass der Supermarkt weiß, was wir einkaufen, und uns dann mit Informationen überflutet – mal abgesehen von NSA, Google und Co., aber das wissen wir ja Gott sei Dank nicht alles.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122378234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pollenallergie gegen Ambrosia: Belastungen, Merkmale und Umgang mit einem importierten Allergieverursacher in Europa","authors":"C. Traidl‐Hoffmann","doi":"10.1159/000492639","DOIUrl":"https://doi.org/10.1159/000492639","url":null,"abstract":"Ambrosia artemisiifolia, also known as common or short ragweed, is an invasive annual flowering herbaceous plant that has its origin in North America. Nowadays, ragweed can be found in many areas worldwide. Ragweed pollen is known for its high potential to cause type I allergic reactions in late summer and autumn and represents a major health problem in America and several countries in Europe. Climate change and urbanization, as well as long distance transport capacity, enhance the spread of ragweed pollen. Therefore ragweed is becoming domestic in non-invaded areas which in turn will increase the sensitization rate. So far 11 ragweed allergens have been described and, according to IgE reactivity, Amb a 1 and Amb a 11 seem to be major allergens. Sensitization rates of the other allergens vary between 10 and 50%. Most of the allergens have already been recombinantly produced, but most of them have not been characterized regarding their allergenic activity, therefore no conclusion on the clinical relevance of all the allergens can be made, which is important and necessary for an accurate diagnosis. Pharmacotherapy is the most common treatment for ragweed pollen allergy but fails to impact on the course of allergy. Allergen-specific immunotherapy (AIT) is the only causative and disease-modifying treatment of allergy with long-lasting effects, but currently it is based on the administration of ragweed pollen extract or Amb a 1 only. In order to improve ragweed pollen AIT, new strategies are required with higher efficacy and safety.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"126 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132022880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Paraneoplastische Syndrome in der Dermatologie - eine Übersicht","authors":"A. Körber","doi":"10.1159/000492631","DOIUrl":"https://doi.org/10.1159/000492631","url":null,"abstract":"A number of paraneoplastic syndromes have been described with gynecological cancers. These syndromes are induced by substances secreted by the tumor or by an immune response triggered by the cancer. Each system of the human body can be affected by different syndromes. Indeed, paraneoplastic syndromes occurring from tumors of the gynecologic tract were found to involve the nervous, ophthalmologic, dermatologic, rheumatologic, endocrine, hematologic and renal systems. These syndromes can manifest before, at the time, or after the diagnosis of cancer. They can also occur at the time of a recurrence. Knowledge about these syndromes is important for physicians caring for patients with cancers, as they can result in severe morbidity and must be treated appropriately. Literature regarding paraneoplastic syndromes associated with tumors of the female genital tract is scattered and the subject has not been reviewed recently. A systematic literature search was thus conducted to identify paraneoplastic syndromes associated with gynecologic cancers. This review focuses on the cancers involved with each paraneoplastic syndrome, and on their pathophysiology, clinical manifestations, possible complications, outcomes, and treatments. As the mainstay of treatment in these conditions is often to address the underlying tumor, it is of upmost importance that physicians be aware of these rare cancer manifestations.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129675805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Morbilliformes Exanthem im Kindesalter: Hinweis auf eine Antibiotika-Allergie","authors":"R. Fölster‐Holst","doi":"10.1159/000492640","DOIUrl":"https://doi.org/10.1159/000492640","url":null,"abstract":"Background: The incidence of rash after aminopenicillin treatment in children with Epstein-Barr Virus (EBV) infection was reported to be 80-100%. A few recent studies suggested that the incidence may be much lower during EBV infection. There are no clear data on the incidence of true drug hypersensitivity among these patients. The aim of this study is to determine the incidence of rash and antibiotic allergy after antibiotic treatment in children with EBV infection. Methods: Drug hypersensitivity was investigated in antibiotic-treated patients with a positive EBV IgM who developed a rash between 2013 and 2016. Results: During the study period, 221 children were diagnosed with EBV infection, and 120 (54.3%) patients were treated with antibiotics during disease. Rash developed in 41 (41/221, 18.6%) patients, and 20 of them (total 120; 16.6%) were treated with antibiotics (most frequently aminopenicillins: 72.5%), and 21 of them (total 101, 20.8%) were not treated with antibiotics (p = 0.43). For 10 of the 20 antibiotic-treated patients with a rash, parents did not consent to an allergy workup. Three of the 10 patients who were tested for drug allergy were proven to have amoxicillin-clavulanate hypersensitivity (30%). Five of the patients without workup reacted after reuse of the suspected drug for infection treatment. Conclusion: In this study, the incidence of drug hypersensitivity was much lower than previously reported. Some of the reactions that occur during infectious mononucleosis are transient, and some are true drug hypersensitivity reactions. Thus, these patients should be evaluated with allergy tests before these drugs are used again after EBV infection.","PeriodicalId":390963,"journal":{"name":"Karger Kompass Dermatologie","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124322388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
